Olema Pharmaceuticals, Inc (OLMA)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Sean Bohen |
| Employees: | 70 |
| Web site: | olema.com |
|
780 BRANNAN STREET, SAN FRANCISCO, CA, 94103
(415) 651-3316
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Olema Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapies for women's cancers. OP-1250, an estrogen receptor antagonist and a selective ER degrader, is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.
Please log in first to see chart